Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Hydroxychloroquine/trametinib

Acquired resistance to hydroxychloroquine and trametinib: case report

    • 10 Accesses

    This is a preview of subscription content, log in to check access.

    Reference

    1. Kinsey C, et al. Myc amplification is a negative biomarker and a resistance mechanism to trametinib/HCQ treatment, but can be overcome by combined palbociclib/HCQ treatment. Cancer Research 79 (Suppl.): abstr. C30, No. 24, Dec 2019. Available from: URL: https://cancerres.aacrjournals.org/content/79/24_Supplement/C30 [abstract]

    Download references

    Rights and permissions

    Reprints and Permissions

    About this article

    Verify currency and authenticity via CrossMark

    Cite this article

    Hydroxychloroquine/trametinib. Reactions Weekly 1790, 128 (2020). https://doi.org/10.1007/s40278-020-74747-8

    Download citation